Many cell-signaling events are regulated through reversible tyrosine phosphorylation of proteins. This phosphorylation cycle is controlled by the counterbalanced actions of two enzyme families, protein tyrosine kinases and protein tyrosine phosphatases (PTPs), each of which has cytoplasmic and receptorlike members. While the regulation and actions of many receptor protein tyrosine kinases (RTKs) are well characterized, our related understanding of the receptor-type PTPs (RPTPs) remains far from complete.
Twenty-one human RPTPs have been identified, and highly conserved orthologues and homologues exist in vertebrates and invertebrates (3) . Several of these RPTPs have particularly well-documented roles in neural development (16, 26, 40) , cell adhesion, and motility (7, 51) . RPTPs are type I transmembrane proteins with varied extracellular domain structures, and in many cases, it is still unclear what their ligands are. It is also unclear how, and in most cases if, such ligands directly control RPTP activity. Moreover, although RTKs are obligate dimers during ligand activation and signaling, dimerization has been demonstrated for only a small number of RPTPs, and we have only a few clues as to how this dimerization is linked to signaling control. Furthermore, it is not clear whether ligand binding is influenced by, or influences, the RPTP dimerization state.
The RPTPs PTP␣, Sap-1, and CD45 form dimers normally in the cell, and this dimerization can block the catalytic action of these enzymes (23, 24, 64) . PTP␣ and CD45 may be inhibited by steric constraints, possibly through an inhibitory wedge structure (8, 29) , although this is still controversial (35) . With PTP␣ and Sap-1, there is also evidence that dimerization and the blockade of catalytic function are stabilized, or even initiated, by oxidation and that cis-dimerization can involve cysteine cross-linkage (57, 59) . PTP can also dimerize, but the influence of this event over enzyme activity is not yet known (12) .
Understanding how RPTP dimerization is related to enzyme inhibition is of great importance, given that the monomeric forms of RPTPs appear to be highly active (14, 30, 37, 54) . The selective suppression of RPTP activity may indeed be essential in cells. Several studies have shown that negative regulation of PTP may enhance nerve growth and even regeneration in adult tissues (32, 46, 56) . Similarly, the negative regulation of a Caenorhabditis elegans RPTP, clr-1, is required for the correct netrin-mediated guidance of anterior ventral microtubule axons in the worm (9) , and inhibition of CD45 through dimerization is necessary for normal lymphoid homeostasis (31) .
Whereas a relationship between RPTP dimerization and enzyme activity is documented, the relationship between RPTP dimerization and ligand interactions is less clear. Several RPTPs interact homophilically, and in one instance, PTP, the interaction model places this enzyme in a multimeric interaction interface, with PTP binding both in cis and in trans (4, 12) . It is not yet clear if cis interactions influence the ability of PTP to undergo trans interactions. One of the heterophilic ligands of PTP, pleiotrophin, can suppress catalytic activity. While it is conceivable that this occurs by inducing PTP dimerization, this has not been directly demonstrated. Recently, an isoform of LAR called LARFN5C, consisting of a single fibronectin type III (FNIII) domain, has been shown to bind homophilically to LAR and may activate it, possibly by favoring the monomer state of LAR (65) . If the biological functions of RPTPs are to be better understood, then the relationships between ligand binding, RPTP dimerization, and RPTP signaling activity must be defined more clearly. Similarly, the structural basis for the differential interactions of RPTP protein isoforms with tissue-specific ligands, as seen with LAR (36) and PTP (45) , for example, must be explained.
In this study, we first investigated the potential dimeric behavior of PTP. PTP is a large, highly conserved cell adhesion molecule-like RPTP that binds several unrelated extracellular ligands (5, 27, 45) . PTP functions in the nervous system to control axon development and regeneration (42, 44, 46, 49, 56) , the maturation and myelination of nerves (15, 33, 60) , and the development of the hypothalamopituitary axis (6, 15, 60) . Nevertheless, little is known about either the biochemical action of this enzyme or the mechanism of ligand interactions. Here, we demonstrate for the first time that PTP exists in a dimeric state in the cell. Significantly, we have also found that only dimeric, and not monomeric, forms of the receptor are able to bind extracellular ligands. Finally, we propose a structural model that may explain the distinct specificities of ligand binding exhibited by different PTP isoforms.
MATERIALS AND METHODS
Epitope tags, mutations, and deletions. The introduction of cysteines in wildtype chicken PTP was carried out using large-template site-directed mutagenesis (62) . Epitope tags were introduced either directly, using insertion of oligonucleotides, or by subcloning of chicken PTP in the expression vector p3xFLAG-CMV25 (Sigma Aldrich). The FNIII domain deletion series was generated by inserting KpnI sites between each pair of FNIII domains and fusing these sites to a KpnI site in pAPTag2 (10) , generating in-frame fusion proteins with placental alkaline phosphatase (PLAP). The fusion points of the sequences were as follows ( (19) . The single hemagglutinin (HA) tag was inserted at the carboxy-terminal end of PLAP by insertion of the sequence 5Ј-AGATCGATCTA CCCATACGACGTCCCAGACTACGCTGCCTAG-3Ј downstream of the BspEI site at the 3Ј end of the PLAP gene in the secretable PLAP vector Aptag4 (10) . To delete most of the ectodomain, generating protein ICD1, PCR was used to amplify bp 2533 to the stop codon of PTP1, and this fragment was ligated between the BglII and XbaI sites of p3XFLAG-myc-CMVTM-25 (Sigma). The site of 5Ј fusion at the BglII site has the sequence 5Ј-AGATCTGATTGATGG AGAGGAA-3Ј. To delete most of the intracellular domain, generating ECD1, a PCR product containing bp 85 to bp 2650 of PTP1 was synthesized using PCR and inserted between the EcoRI and XbaI sites of p3XFLAG-myc-CMVTM-25 (Sigma); this vector supplies a peptide secretion signal upstream of the triplecopy FLAG. The 5Ј site of fusion was 5Ј-GAATTCGGAAAGTCCCC-3Ј, and the 3Ј site was 5Ј-AACGGAAAGTCTAGA-3 (the vector sequence is in boldface). The flexible linker was created by annealing the oligonucleotides 5Ј-GTAC GGGCGGAGGAGGATCCGGAGGTGGCGGTTCACCGG-3Ј (sense) and 5Ј-GTACCCGGTGAACCGCCACCTCCGGATCCTCCTCCGCCC-3Ј (antisense) and inserting them in frame into an Asp718 (Kpn1) site in FN5d-AP and FN6d-AP.
Transfections, immunoprecipitation, immunofluorescence, and PLAP assays. DNA vectors were transfected into HEK293T cells using standard calcium phosphate methods. For the cysteine mutations, cells were lysed in 1% Nonidet P-40, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 7 g/ml pepstatin A, 1.5 g/ml aprotinin, 2 mM phenylmethylsulfonyl fluoride with or without 20 mM iodoacetamide. For other proteins, cells were lysed in 50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100 plus protease inhibitors (Complete; Roche). For immunoprecipitation, lysates were incubated with antibodies specific for FLAG (Clone M2; Sigma Aldrich, United Kingdom), HA (3F10 [Roche] or HA-7 [Sigma Aldrich, United Kingdom]), or myc (9E10; Sigma Aldrich, United Kingdom) epitopes, and antibody-antigen complexes were purified using protein G Sepharose (Upstate).
For immunofluorescence, cells were fixed 3 days posttransfection in ice-cold 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min, rinsed in PBS, and quenched for 5 min in 2% glycine-PBS. The fixed cells were permeabilized for 5 min in 0.1% Triton X-100, 0.05% sodium dodecyl sulfate (SDS)-PBS. Coverslips were incubated with primary anti-HA and anti-FLAG for 45 min at 37°C. After the PBS washes, secondary anti-rat tetramethyl rhodamine isothiocyanate-conjugated or anti-mouse-fluorescein isothiocyanate-conjugated antibodies (Dako, United Kingdom) were added. The coverslips were washed and mounted with Fluorsave (Calbiochem).
Analysis of disulfide dimers. Cells were transfected and lysed as described above in the presence of 20 mM iodoacetamide. Protein concentrations were estimated using the Bradford method. After polyacrylamide gel electrophoresis (PAGE), the gels were transferred to polyvinylidene difluoride membranes in 25 mM Tris, 192 mM glycine, 20% methanol. For two-dimensional (2D) gel analysis, protein samples were first subjected to 1D PAGE as described above, except that samples were boiled in 5% SDS, 25% glycerol, 156 mM Tris-HCl, pH 6.8, 50 mM N-ethylmaleimide for 30 s beforehand. Following 1D PAGE, the gels were stained with zinc (Bio-Rad Zinc Stain [18] ), and the lanes were excised; destained; incubated in 1ϫ Laemli with or without 5% ␤-mercaptoethanol plus 50 mM N-ethylmaleimide at 100°C for 5 min; washed twice in 1% SDS, 10% glycerol, 62.5 mM Tris-HCl, pH 6.8, for 5 min to remove reducing agents; and then cast on top of a 4% stack-6% resolving gel.
Immunoblotting. After the gels were transferred to polyvinylidene difluoride membranes, the membranes were blocked with 10% dry milk powder in Trisbuffered saline overnight before the addition of antibody for 1 h. The primary antibodies used were anti-FLAG (M2; Sigma); anti-HA (HA-7; Sigma); and IG2, anti-PTP (52) . The filters were washed three times in Tris-buffered saline plus 0.2% Tween 20 before the addition of horseradish peroxidase-conjugated secondary antibodies for 1 h. Horseradish peroxidase was detected with ECL ϩ (Amersham Biosciences, United Kingdom).
Bis(sulfosuccinimidyl)suberate cross-linking. A PTP1 cDNA was cloned into pTre2 (Clontech) and transfected into PC12 Tet-On cells (Clontech). One selected clone, 12CRYP11, exhibited background levels of PTP expression and 5ϫ to 10ϫ inducible expression. Cells were cultured in Dulbecco's modified Eagle's medium, 10% horse serum, 5% fetal calf serum on a collagen IV substrate. The medium was replaced with PBS containing 5 mM bis(sulfosuccinimidyl)suberate (Pearce, Rockford, IL) for 30 min at 4°C, and then Tris-Cl (pH 7.5) was added to a final concentration of 20 mM for 15 min at room temperature. The cells were then washed briefly in ice-cold PBS and lysed in 50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100 plus protease inhibitors (Complete; Roche). Equal amounts of nonreduced lysates were separated by PAGE and immunoblotted using IG2 serum raised against the PTP ectodomain (52).
Purification of FN3d-AP and PLAP-HA. One-milliliter aliquots of anti-PLAP agarose and anti-HA agarose (Sigma Aldrich) were packed into fast protein liquid chromatography columns (Amersham Biosciences). The columns were equilibrated using 5 column volumes of 0.05 M Tris, 0.5 M NaCl (pH 8.0), and 200 ml of precleared, conditioned medium was loaded onto the column. The columns were washed with 5 column volumes of the equilibration buffer, and the bound components were eluted with 0.05 M glycine, 0.5 M NaCl (pH 2.8). Fractions (500 l) were neutralized with 50 l of 1.0 M Tris-HCl (pH 9.0), pooled, and desalted using PD10 desalting columns (Amersham Biosciences), and the protein purity was determined by SDS-PAGE on a 6% Tris-glycine gel stained with a PlusOne silverstaining kit (Amersham Biosciences). Immunoblotting was done with the anti-PTP antibody IG2 (52) . Band intensities were measured using a GS-800 calibrated densitometer and Quantity One software (Bio-Rad).
RAP and solid-phase alkaline phosphatase assays. Receptor affinity probe (RAP) affinity assays were performed with PLAP fusion proteins as previously described (20) . PLAP fusion proteins were first collected in cell culture supernatants, and aliquots were subjected to PAGE before immunoblotting and detection with the anti-PTP serum IG2 (52) , confirming the fusion protein size and integrity. Solid-phase assays were carried out using plasma polymer-prepared 96-well microplates (Plasso Technology Ltd., Sheffield, United Kingdom; product code P100) designed to bind heparin. Duplicate wells were incubated overnight at 4°C with 200 l of heparin (20 g/ml) per well. Bovine serum albumin (BSA)-PBS (2%) was used as a negative control for coating. After the plates were washed, a blocking solution of 5% BSA-PBS-0.05%Tween 20 was added at 37°C for 1 h; 200 l of fusion protein was then added for 1 h at room temperature. After the plates were washed, 200 l of secreted alkaline phosphatase buffer containing 12 mM p-nitrophenyl phosphate was added. The PLAP activity was measured for 20 min at 405 nm at room temperature, mean values were taken, and control values from BSA-coated wells were used to normalize all values.
RESULTS

Construction of PTP variants with unpaired cysteines.
To determine whether PTP can exist in a homodimeric state in live cells, unpaired cysteines were introduced in the extracellular juxtamembrane region using site-directed mutagenesis. Cysteines were introduced at four sites, all carboxy terminal to the primary, furin-like protease cleavage site predicted in PTP (47) (Fig. 1A ). These cysteine positions should also be amino terminal to a putative secondary matrix metalloproteinase cleavage site detected in human PTP (amino acids 843 to 844) (47) , except for mutation sites 843 and 845, which would be within this site (Fig. 1A) . If PTP forms dimers, the unpaired cysteines may form covalent linkages, thus "trapping" the protein in the dimeric state. The cysteines were placed 2 amino acids apart to try to ensure that several rotational faces of the peptide structure would be exposed to potential crosslinking (Fig. 1B) . The proteins were expressed in HEK293T cells and tested for correct expression on the cell surface. Under the conditions used, the cells were mostly fusiform or rounded in phenotype, and the expression of wild-type (wt) PTP and the mutants had no obvious effect on this phenotype. Figure 1 shows that each protein had prominent cell surface localization similar to that seen with wt PTP (Fig. 1E to H). The wt PTP protein gave similar surface localization when detected with either extracellular or intracellular epitopes ( Fig. 1C and D) . The variant PTP proteins were then analyzed by immunoblotting. The pattern of wt PTP expression in HEK293T cells was complex, and a schematic of the predicted fragments is shown in Fig. 2E . In tissues, PTP1 is thought to be cleaved at a conserved basic region in the ectodomain (Fig. 1A [PCS] and 2E), which is a site found in all LAR-related RPTPs (41) . Cleavage produces a membrane-spanning fragment of ϳ85 kDa ( Fig. 2A , HA band 3, and E, fragment 3) and an 81-kDa ectodomain fragment (Fig. 2C , FLAG band 2, and E, fragment 2). Upon overexpression of PTP1, two further proteins were seen. First, a full-length uncleaved protein (theoretical mass, 166 kDa) was generated ( Fig. 2A ; C, band 1; and E, protein 1), probably due to the inability of cells to process all of the overexpressed protein. A second cleavage event was also observed at various levels between experiments, producing an HA-tagged band of 75 kDa ( Fig. 2A, HA band 4 , and E, fragment 4). A similar cleavage event has been described for LAR-like RPTPs and usually occurs subsequent to the primary cleavage (1, 47) . However, we also observed a FLAG-tagged protein of 90 kDa, which we predict has undergone secondary cleavage without prior primary cleavage (Fig. 2C , FLAG band 5, and E, fragment 5). Although, again, this may be partly an artifact of overexpression, it nonetheless proved useful in analyzing the cysteine dimer data (see below). Under reducing conditions, each mutated protein exhibited a proteolytic pattern similar to that of wt PTP ( Fig. 2A and C) . Dimers identified by cysteine cross-linking. The same lysates described above were subjected to PAGE under nonreducing conditions ( Fig. 2B and D) . The wild-type protein gave a banding pattern very similar to the previous one. In contrast, the mutated forms of PTP showed large amounts of reduction-sensitive, high-molecular-mass forms of around 300 to 350 kDa, consistent with their being dimers or multimers of uncleaved PTP ( Fig. 2B ; D, band 6; and E, dimer 6). In nonreduced samples, additional FLAG bands appeared at approximately 180 kDa (Fig. 2D, band 8) , and concurrently, the 90-kDa bands (band 5) were greatly reduced in intensity (compare bands 5 in Fig. 2C and D) . The 180-kDa bands are therefore predicted to be dimers of the cleaved 90-kDa ectodomain fragment 5 (Fig. 2E, dimer 8) . We also predict that under nonreducing conditions, the 85-kDa HA band 3 would dimerize and run at approximately the same size as the uncleaved band 1 (Fig. 2B, bands 1 and 7 , and E, dimer 7). In support of this, most of the 85-kDa bands are no longer found under nonreducing conditions (Fig. 2B) . To further support these predictions, a 2D gel study was carried out with P839C protein. After P839C was separated under nonreducing conditions, a second dimension was run under reducing and nonreducing conditions (Fig. 2F to I ). Upon reduction, the 180-kDa band 8 dropped in size to the predicted 90-kDa spot 5 (Fig. 2G) . Moreover, using the HA tag, a proportion of bands "1 and 7" also dropped to the predicted smaller size of band 3, consistent with some of the "1 and 7" band being band 3 dimers (Fig. 2I) . Note that this technique does not give quantitative reduction of first-dimension proteins, thus leaving some nonreduced bands present as well. It was also noted that no convincing evidence was seen of bands resembling heterodimers of, for example, band 1 with band 5 or band 1 with band 3.
These data collectively show that when trapped with unpaired cysteines, high levels of dimeric PTP can be identified in cells and that these are predominantly homodimers of the same cleavage states.
Dimerization of wild-type PTP. Given that PTP dimers could be readily trapped in a cross-linked form by ectopic cysteines, we next wanted to determine whether homodimers of wt PTP could be identified in cell lysates. Modified forms of the protein were generated with either an amino-terminal FLAG tag or a carboxy-terminal HA tag. They were cotransfected and immunoprecipitated with one tag, and then the other tag was immunodetected. PTP could be coimmunoprecipitated efficiently in both directions, indicating the presence of significant levels of cis homodimers made up of cleaved or uncleaved forms of wt PTP (Fig. 3) .
To extend this study, we carried out BS 3 cross-linking in cells that expressed relatively low levels of PTP. A doxycyclineinducible PC12 neuronal cell line derivative was constructed, expressing either low (uninduced) or approximately fivefoldhigher (induced) levels of wt PTP. Without induction, the cells expressed low levels of the fully cleaved type 2 (nonreduced 75-kDa) protein (Fig. 3E) , similar to the situation seen in neuronal cells in vivo (52, 53) . BS 3 cross-linking of live cells caused the loss of 75-kDa bands and the appearance of bands at approximately 140 kDa, consistent with 75-kDa dimer formation. There was always an extended background smear, with another commonly seen band of unknown origin appearing at 100 kDa, suggesting that PTP exhibits variable cross-linking to other cellular proteins as well (Fig. 3E) . A similar qualitative pattern was seen in the cells after doxycycline-induced expression of higher PTP levels (Fig. 3E) . These data suggest that PTP dimers can be cross-linked at both low and high expression levels of PTP and that much of the protein is exposed at the cell surface.
Transmembrane proteins that undergo intramembranous dimerization, including RPTPs, can form interaction interfaces through extracellular, intracellular, and transmembrane regions (11, 23, 48, 61) . Two FLAG-tagged forms of PTP were constructed to identify which domains of PTP facilitate its cis interactions. Protein ICD-1 contains PTP1 sequence starting at amino acid 845 in the juxtamembrane region (Fig. 4D) . Protein ECD-1 contains all of the ectodomain, stopping at amino acid 883 just inside the cell ( Fig. 1 and 4D ). These two proteins overlap by 39 amino acids, including the whole transmembrane region.
The proteins were coexpressed with wild-type protein, and coimmunoprecipitations were performed. Both ECD-1 and ICD-1 bound to the full-length protein (Fig. 4A and B) , with ICD1 consistently binding to wt PTP much more efficiently than did ECD-1. For example, no band 3 form of wt PTP was observed associating with ECD1, and only very faint bands 1 and 4 were seen (Fig. 4A) . Poor accessibility to FLAG is not an explanation, since the coprecipitation of all three wt PTP double-headed arrows indicate cysteine bridges in covalent dimers; the black dots and white dots in panel E represent FLAG and HA tags, respectively. FLAG-tagged PTP ectodomains run smaller under nonreducing conditions due to their compact immunoglobulin domain content. Panels F to I show 2D-PAGE analysis of P839C PTP proteins. P839C proteins were separated by PAGE and then run in a second, orthogonal dimension under nonreducing (F and H) or reducing (G and I) conditions (reduction is not complete). The protein spots indicated by arrows correspond to the protein numbers in E. Molecular mass markers are indicated to the left of each panel.
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ protein bands was seen (Fig. 4A, lane 3, middle) . The data currently suggest, therefore, that the transmembrane and catalytic domains together contribute most of the interaction affinity between PTP molecules. It was also noted that ICD-1 pulled down the primary cleaved form of PTP most efficiently, with little if any uncleaved form being observed even after prolonged filter exposure (Fig. 4A, band 3, lane 7) . Since ECD-1 and ICD1 overlap in the transmembrane region, we cotransfected the two proteins and asked whether they would also associate. When immunoprecipitated with an ectodomain-directed antibody, IG2 (52), ECD1 could efficiently pull down ICD1 (Fig. 4C) . Therefore, a significant amount of the interaction interface between PTP dimers occurs in the transmembrane region and its immediate surrounding sequences.
PTP requires dimerization for ligand binding.
It is not understood whether the extracellular ligands of RPTPs generally bind to monomeric or dimeric forms of the receptors. This information could prove very useful, since it may provide an understanding of the ligand-dependent regulation of RPTPs. Assays of ligand binding to PTP in live cells are not currently available, so we have instead developed a novel RAP strategy to begin to address this question. This assay allowed us to examine the stoichiometry of interactions between soluble PTP-AP fusion proteins and two PTP ligands, the HSPGs (5) and muscle-bound nucleolin (2, 45) .
Standard RAP probes consist of a receptor ectodomain fused to PLAP. Since PLAP is active only as a dimer (22) , by definition we detect only oligomers of paired ectodomains using the PLAP readout. To test instead whether RPTP ectodomain monomers have any ligand binding function, a method was established using heterodimers of the ectodomain-PLAP with PLAP. An HA-tagged form of secreted PLAP was constructed (PLAP-HA) and cotransfected into 293T cells, along with the PTP-AP probe (Fig. 5A) . This allowed cells to secrete three protein complexes: (i) homodimers of full-length PTP-AP, (ii) homodimers of PLAP-HA, and (iii) heterodimers of PLAP-HA-PTP-AP (Fig. 5A) . Cell superna- tants were passed through an anti-HA affinity column to purify the PLAP-HA proteins. The PLAP homodimer has no binding activity in RAP assays; therefore, any binding activity in the affinity-purified mixture should come only from PLAP-HA-PTP-AP heterodimers. During affinity purification, the flowthrough (containing PTP-AP homodimers) was shown to have RAP activity (data not shown), confirming that the purification did not affect its binding competence. Two proteins were then tested in the RAP assay, one an affinity-purified positive control of PTP-AP homodimers (purified using anti-PLAP antibody; see Materials and Methods) and the other the purified heterodimer (PLAP-HA-PTP-AP). Fractions of these protein solutions were first immunoblotted using anti-PTP antibodies, to allow us to normalize for PTP ectodomain content. They were then applied to tissue sections for RAP assays (Fig. 5D to G) . This revealed that the monomeric PTP-AP had no detectable ligand binding activity ( Fig. 5D and F) , even when RAP reactions were allowed to run overnight. A second experiment was carried out with the monomeric form of PTP-AP, to address directly whether the monomer could bind to purified heparin, a polysaccharide known to bind to this protein. This assay was carried out in solid phase, with heparin-coated 96-well plates (supplied by PLASSO Ltd., United Kingdom). Normalized amounts of the PLAP fusion proteins were added to the plates in solution, and their binding capacities were measured. Again, the monomeric form of the ectodomain had no significant affinity for heparin (Fig. 5H) . These RAP and solid-phase affinity data therefore support the conclusion that the PTP ectodomain must be in a dimeric structure in order to bind ligands efficiently.
Dimerization influences isoform specificity. The two main protein isoforms of PTP have either four (PTP1) or eight (PTP2) FNIII-type domains, and these isoforms have distinct ligand binding capacities (20, 45, 50) . As demonstrated above, ligand interactions require a dimerized PTP structure, at least in vitro. This led us to investigate whether the ligand binding specificities of PTP1 and PTP2 are con- A protein deletion series was constructed from PTP2 in which FNIII subdomains were deleted progressively from the carboxy terminus. Our previously reported PTP-AP probes were fused to PLAP at alanine residue 1124 in PTP, approximately 27 amino acids downstream of FNIII domain 8 (taken as ending in the sequence KPE) (20) . Both PTP1-AP and PTP2-AP thus have 119 amino acids in common at their carboxy-terminal ends. The current deletion series started with construct FN8d-AP, which had the non-FNIII stretch of 27 amino acids deleted. This was followed by progressive deletion of FNIII domains (FN7d-AP to FN1d-AP). Each fusion protein was expressed in 293T cells and identified in the supernatant by immunoblotting (Fig. 6 ). This enabled us to confirm their predicted sizes and to normalize for the amounts of PLAP fusion proteins present. These normalized probes were then screened for their ligand binding properties (Fig. 7) .
We monitored the binding of probes to two different ligand types: (i) HSPG ligands in basement membranes (BMs) (5) and (ii) a non-HSPG ligand in skeletal muscle, a component of which is nucleolin (2, 45) . Proteins FN1d-AP, FN4d-AP, and FN5d-AP had no detectable binding capacity, and FN2d-AP had extremely low activity (Fig. 7) . Proteins with fewer domains than FN1d-AP also had no activity (data not shown). In contrast, FN3d-AP and FN7d-AP had strong binding capacities, similar qualitatively to that of PTP1-AP (Fig. 7A, E , and I). These proteins bound to both BMs and muscles. FN8d-AP had some weak RAP activity (Fig. 7J) , and Fn6d-AP had stronger activity (Fig. 7H ), but both of these probes bound in similar fashions to PTP2-AP, with little if any muscle binding (Fig.  7B) . The binding specificities of these deletion forms are summarized in Fig. 8A .
The data indicate that the amino-terminal segment consisting of the immunoglobulin domains and the first three FNIII domains, is a region that is sufficient for ligand binding. With ectodomains larger than FN3d, there was no simple correlation between the presence of specific FNIII domains and the relative ability to bind specific ligands. This suggests that some factor other than simply FNIII domain content is influencing the specificity of ligand binding. It is possible that some of these artificial deletion forms are simply incapable of ligand binding due to gross protein misfolding. Nevertheless, given that these constructs are all anchored to dimerized PLAP, it is more likely that the ligand binding capacities of these ectodomains are being restricted by rotational constraints. If so, this might indicate that there are only a limited number of energetically favorable rotational conformations in dimers of the PTP ectodomain, resulting in either a PTP1-or PTP2-like ligand binding pattern (Fig. 7A and B) . To test whether ligand binding potential can be recovered by simply providing greater rotational freedom, we reengineered FN5d-AP by inserting a flexible linker, GGGGSGGGGSPGT, between the PTP ectodomain and PLAP in FNd5-AP (Fig. 8B) . The resulting protein, FN5L-AP (Fig. 8A) , was then tested for its RAP activity in comparison to FN5d-AP. The addition of the linker to FN5d-AP caused a striking recovery of RAP binding activity, so that FN5L-AP now quite closely resembled FN3d-AP ( Fig. 8C-H) . These data suggest that PTP dimers can fall broadly into one of two different conformations with the distinct ligand binding specificities of PTP1 or PTP2. We suggest that the alternative FN4 to -7 region found in PTP2 affects the ligand binding specificity largely by forcing the amino-terminal ligand binding region into a novel rotational state.
DISCUSSION
This study has shown that the CAM-like RPTP, PTP, is homodimerized in the cell and that dimerization is not greatly influenced by the posttranslational proteolytic state of the protein. Our data further reveal that PTP requires dimerization to bind to its ligands, since monomeric ectodomains have no ligand binding capacity, at least under in vitro conditions. Lastly, our data also now indicate that the distinct ligand binding capacities of two major PTP isoforms are brought about through their alternative use of FNIII domains, which in turn imposes distinct rotational or flexional constraints on their ectodomain dimers.
PTP can dimerize efficiently in the cell, and we found that the transmembrane and juxtamembrane regions are sufficient for at least some of this interaction. Nevertheless, the data suggest that the intracellular and, to a lesser extent, the extracellular domain of the protein also contribute. This is similar to the situation with several other receptors, including PTP␣ and RTKs (11, 23, 48, 61) . Dimers are found between uncleaved PTP proteins and between fully cleaved forms of PTP. It therefore seems unlikely that cleavage per se is necessary for dimerization. This study used four cysteine-containing mutations in the juxtamembrane domain region, all of which trapped PTP in its dimerized state. All of the mutated proteins underwent a juxtamembrane cleavage carboxy terminal to their cysteine bridges. Given that the secondary cleavage site (*) in rat PTP is in the amino acid sequence DPQP*IVD
846
(1), our data indicate that, at least for I845C, the avian PTP cleavage is more carboxy terminal. This suggests either that there is little sequence specificity or that the replacement of mammalian valine 845 in PTP with isoleucine in the chicken may alter the cleavage specificity.
RPTPs, such as PTP␣, CD45, and SAP-1, exist as homodimers, and this is believed to negatively regulate catalytic (17, 21, 38, 63) . In some cases, RTKs are monomeric, and ligand binding then induces dimerization. Ligands can either form a cross-link in a receptor dimer (63) or allosterically trigger a receptor-only dimerization event (17) . In other receptors, such as those for insulin (38) or erythropoietin (43) , the receptors are already dimerized and ligand binding induces conformational changes and receptor activation. With RPTPs, the relationships between ligand binding, dimerization, and changes in RPTP activity have proved difficult to assess. RPTP dimers are potentially inactive, while monomers are likely to be highly active (13, 14, 29, 54, 58, 59 (65) . A similar situation is seen with CD45-associated protein, which associates with CD45 in cis and reduces dimer formation, consequently activating CD45 (54) . The general picture concerning the influence of ectodomain ligands over RPTP function has therefore yet to be formed. PTP can bind to at least three extracellular ligands (5, 27, 45) . Although the role of ligand interactions is currently unclear, it is likely that they influence the biological functions of this phosphatase (6, 15, 33, 42, 44, 46, 49, 56, 60) . Because it has not proven technically possible to test the behavior of ligand binding to PTP in live cells, we chose a complementary approach instead. This examined how soluble PTP ectodomains bind to heterotypic ligands in vitro. The most significant finding is that PTP binds to these ligands only when it is presented as a dimer. The ligands we have tested include HSPGs and a muscle site that includes nucleolin (2) . HSPGs have been shown to modulate PTP interactions with retinal axon receptors (44) , and HSPGs have been shown to interact functionally with DLAR, a Drosophila ancestor of PTP, during motor axon guidance and synaptogenesis (19, 25) . Such HSPGs may therefore be binding to preexisting PTP dimers during these events. To understand whether such ligand binding alters the catalytic function of the dimer, we must await assays that can directly quantify the activation state of PTP in the cell.
PTP is expressed as two major protein isoforms (50) . The longer isoform, PTP2, is distinct from PTP1 in being unable to bind to skeletal-muscle ligands (20, 45) . It has been a puzzle why the increased number of FNIII domains in PTP2 should apparently result in different or possibly fewer ligand partners. The current study demonstrates that the ligand binding specificity does not correlate straightforwardly with the FNIII domain content. For example, FN7d has all of the unique domains of PTP2 (FN4 to -7), but unlike PTP2, it does bind to muscle. On the other hand, addition of the final FN8 domain to FNd7-AP causes loss of muscle interaction: however, FN8 is found in PTP1, which does bind muscle. We have also ruled out a simple effect of increasing ectodomain length on ligand binding specificity, since FN6d-AP behaves like PTP2, whereas the longer FNd7-AP again behaves like PTP1. The lack of a straightforward relationship between the ligand binding specificity and the FNIII content, together with the sensitivity of ligand binding to small increments in protein length, suggests that ligand binding is defined by additional molecular constraints. We propose a parsimonious model in which the binding patterns of PTP1 and PTP2 reflect alternative rotational conformers of the dimerized ectodomains. FNIII domains form relatively inflexible, rod-like structures (28) . One effect of adding four FNIII domains to PTP1 to produce PTP2 (5), therefore, might be to induce a new conformational or rotational change in the region amino terminal to FNIII domain 4, having the effect of masking the muscle binding site while retaining the HSPG binding site. From our deletion series, it appears that all ligand binding is effected by this amino-terminal region contained within FN3d-AP. If this model of regulation using rotational conformation holds true, then we predict that some of the alternatively encoded exons found in the related RPTPs LAR and PTP␦ (41, 66) could also be imposing novel rotational conformations on ectodomain dimers. Multiple ligand types might therefore be able to bind to different RPTP isoforms through two distinct mechanisms, first, through the intrinsic binding properties of alternative peptide inserts (36) , and second, through larger-scale conformational changes in the molecules.
One important question to be answered is whether rotational conformation is an intrinsic property of ectodomains or whether it can be imposed in an "inside out" manner by intracellular domains. Data using PTP␣ suggest that for type IV RPTPs, this is possible (57) . Similarly, we need to address the possibility that ligand binding "locks" ectodomain dimers into distinct rotational conformations that in turn differentially influence intracellular signaling. Our current data indicate that the addition of soluble heparin to PTP-expressing cells does not affect the overall degree of dimerization that we can detect in the cells (C. Faux and S. Lee, unpublished data).
One problem that has dogged the RPTP field is the relatively poor success in identifying ligands using ectodomain fusion assays. We have now demonstrated that, with PTP at least, the rotational freedom of the ectodomain with respect to PLAP plays a highly critical role in determining whether ligand binding capacity is retained. This could now prove useful in the future application of this RAP assay in ligand characterization.
In summary, we have shown for the first time that PTP is dimerized in the cell and that ectodomain dimerization is necessary for heterophilic ligand binding. We also provide new mechanism available to it to control its ligand binding potential. These findings could have important implications for our understanding of how heterophilic ligands interact with, and potentially regulate, RPTPs.
